Citations

Clear

2117 citation(s) found for "Mayo, Steven".

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Dy, Grace K. , Thomas, James P. , Wilding, George, Bruzek, Laura M., Mandrekar, Sumithra J. , Erlichman, Charles , Alberti, Dona, Binger, Kim, Pitot, Henry C., Hanson, Lorelei J., Marnocha, Rebecca, Tutsch, Kendra D., Adjei, Alex A. , Alberts, Steven R. , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 9 | Pages: 3410-3416

10.1158/1078-0432.ccr-04-2068 | PMID 15867242 Get It

Abstract Purpose: To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies. Patients and Methods: Twenty-eight patients (14 male and 14 female) received PS-341 twice weekly for 4 of 6 weeks (schedule I). Because toxicity necessitated dose omissions on this schedule, 16 additional patients (12 male and 4 female) received PS-341 twice weekly for 2 of every 3 weeks (schedule II). A total of 73 courses of treatment was given (median, 2; range, 1-4). Inhibition of 20S proteasome activity in peripheral blood mononuclear cells (PBMC) and accumulation of proteasome-targeted polypeptides in tumor tissue were evaluated as pharmacodynamic markers of PS-341 activity. Results: The most common toxicity was thrombocytopenia, which was dose limiting at 1.7 mg/m2 (schedule I) and 1.6 mg/m2 (schedule II), respectively. Sensory neuropathy was dose-limiting in a patient in schedule I. Grade ≥3 toxicities for schedule I were constipation, fatigue, myalgia, and sensory neuropathy. Grade ≥3 toxicities for schedule II were dehydration resulting from diarrhea, nausea and vomiting, fatigue, hypoglycemia, and hypotension. The maximum tolerated dose was 1.5 mg/m2 for both schedules. Reversible dose-dependent decreases in 20S proteasome activity in PBMCs were observed, with 36% inhibition at 0.5 mg/m2, 52% at 0.9 mg/m2, and 75% at 1.25 mg/m2. Accumulation of proteasome-targeted polypeptides was detected in tumor samples after treatment with PS-341. A patient with multiple myeloma had a partial response. Conclusion: PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied.
Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers
Debes, José D. , Roberts, Rosebud O., Jacobson, Debra J., Lieber, Michael M., Tindall, Donald J., Jacobsen, Steven J. , Girman, Cynthia J.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 20, 2005 | Volume: 13 | Issue: 2 | Pages: 255-259

10.1158/1055-9965.epi-03-0093 | PMID 14973089 Get It

AbstractCalcium channel blockers block calcium signal-mediated apoptosis. It is hypothesized that the use of these drugs may be associated with the development of cancer. This study investigated the association between daily use of calcium channel blockers and prostate cancer in a community-based cohort of men who participated in a longitudinal study of lower urinary tract symptoms. Study subjects were men ages 40 to 79 years by January 1, 1990, and were randomly selected from Olmsted County in Minnesota. At baseline, participants underwent an interview to determine all medications taken on a daily basis, including calcium channel blockers and to elicit a family history of prostate cancer. During follow-up, all men with a histological diagnosis of prostate cancer were identified through patient self-report and by a review of the complete medical record. Over 12,668 person years of follow-up, 15 (6.8%) of 220 calcium channel blocker users and 120 (10.5%) of 1142 nonusers developed prostate cancer (P = 0.09; odds ratio, 0.62; 95% confidence interval, 0.36–1.10). With adjustment for age and family history of prostate cancer, the risk (odds ratio, 95% confidence interval) of prostate cancer was 0.55 (0.31–0.97) in calcium channel blocker users compared with nonusers. In analyses stratified by family history of prostate cancer, the risk of prostate cancer was 0.45 (0.23–0.88) in men without a family history and 2.64 (0.82–8.47) in men with a family history of prostate cancer (P = 0.006). These findings suggest an association between prostate cancer and daily use of calcium channel blockers that varies by family history of prostate cancer.
A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk
Narla, Goutham , DiFeo, Analisa , Reeves, Helen L. , Schaid, Daniel J. , Hirshfeld, Jennifer, Hod, Eldad A. , Katz, Amanda, Isaacs, William B., Hebbring, Scott J. , Komiya, Akira , McDonnell, Shannon K. , Wiley, Kathleen E. , Jacobsen, Steven J. , Isaacs, Sarah D., Walsh, Patrick C., Chang, Bao-Li, Friedrichsen, Danielle M., Stanford, Janet L. , Ostrander, Elaine A. , Chinnaiyan, Arul M., Rubin, Mark A. , Xu, Jianfeng , Thibodeau, Stephen N. , Martignetti, John A., Karyadi, Danielle M. , Zheng, Shusen , Chang, Bao‐Li, Friedman, Scott L. , DiFeo, Analisa , Rubin, Mark A , McDonnell, Shannon K

Mayo Clinic

Cancer Research | September 15, 2005 | Volume: 65 | Issue: 4 | Pages: 1213-1222

10.1158/0008-5472.can-04-4249 | PMID 15735005 Get It

Abstract Prostate cancer is a leading and increasingly prevalent cause of cancer death in men. Whereas family history of disease is one of the strongest prostate cancer risk factors and suggests a hereditary component, the predisposing genetic factors remain unknown. We first showed that KLF6 is a tumor suppressor somatically inactivated in prostate cancer and since then, its functional loss has been further established in prostate cancer cell lines and other human cancers. Wild-type KLF6, but not patient-derived mutants, suppresses cell growth through p53-independent transactivation of p21. Here we show that a germline KLF6 single nucleotide polymorphism, confirmed in a tri-institutional study of 3,411 men, is significantly associated with an increased relative risk of prostate cancer in men, regardless of family history of disease. This prostate cancer–associated allele generates a novel functional SRp40 DNA binding site and increases transcription of three alternatively spliced KLF6 isoforms. The KLF6 variant proteins KLF6-SV1 and KLF6-SV2 are mislocalized to the cytoplasm, antagonize wtKLF6 function, leading to decreased p21 expression and increased cell growth, and are up-regulated in tumor versus normal prostatic tissue. Thus, these results are the first to identify a novel mechanism of self-encoded tumor suppressor gene inactivation and link a relatively common single nucleotide polymorphism to both regulation of alternative splicing and an increased risk in a major human cancer.
LONGITUDINAL CHANGES IN POST-VOID RESIDUAL AND VOIDED VOLUME AMONG COMMUNITY DWELLING MEN
Jacobson, Debra J., McGree, Michaela E. , Lieber, Michael M., Jacobsen, Steven J. , Rule, Andrew D. , Girman, Cynthia J.

Mayo Clinic

Journal of Urology | September 13, 2005 | Volume: 174 | Issue: 4 Part 1 | Pages: 1317-1322

10.1097/01.ju.0000173922.29275.54 | PMID 16145411 Get It

Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following measles–mumps–rubella-II (MMR-II) vaccination
Dhiman, Neelam , Ovsyannikova, Inna G. , Ryan, Jenna E., Jacobson, Robert M. , Vierkant, Robert A. , Pankratz, V. Shane , Jacobsen, Steven J. , Poland, Gregory A. , Vierkant, Robert A , Jacobson, Robert M

Mayo Clinic

Clinical and Experimental Immunology | September 11, 2005 | Volume: 142 | Issue: 3 | Pages: 498-504

10.1111/j.1365-2249.2005.02931.x | PMID 16297162 Get It

SummaryImmunity to measles is conferred by the interplay of humoral and cellular immune responses, the latter being critical in maintaining long-term recall response. Therefore, it is important to evaluate measles-specific humoral and cellular immunity in populations several years after vaccination and understand the correlations among these measures of immunity. We examined measles-specific antibodies, lymphoproliferation and the Th1/Th2 signature cytokines, interferon (IFN)-γ and interleukin (IL)-4, in a population-based cohort of healthy children from Olmsted County, Minnesota after two doses of measles–mumps–rubella-II (MMR-II) vaccine. We detected positive measures of measles-specific cellular and humoral immunity in the majority of our study population. However, a small proportion of subjects demonstrated an immune response skewed towards the Th2 type, characterized by the presence of either IL-4 and/or measles-specific antibodies and a lack of IFN-γ production. Further, we observed a significant positive correlation between lymphoproliferation and secretion of IFN-γ (r = 0·20, P = 0·0002) and IL-4 (r = 0·15, P = 0·005). Measles antibody levels were correlated with lymphoproliferation (r = 0·12, P = 0·03), but lacked correlation to either cytokine type. In conclusion, we demonstrated the presence of both long-term cellular and humoral responses after MMR-II vaccination in a significant proportion of study subjects. Further, a positive correlation between lymphoproliferation and IL-4 and IFN-γ suggests that immunity to measles may be maintained by both Th1 and Th2 cells. We speculate that the Th2 biased response observed in a subset of our subjects may be insufficient to provide long-term immunity against measles. Further examination of the determinants of Th1 versus Th2 skewing of the immune response and long-term follow-up is needed.
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer
Cynthia, X. , Thomas, Sachdev , Mandrekar, Sumithra J. , Nikcevich, Daniel A., Rowland, Kendrith M. , Fitch, Tom R., Windschitl, Harold E., Hillman, Shauna L., Schild, Steven E. , Jett, James R., Obasaju, Coleman K., Adjei, Alex A. , Nair, Suresh , Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | August 31, 2005 | Volume: 23 | Issue: 25 | Pages: 5929-5937

10.1200/jco.2005.13.953 | PMID 16135464 Get It

Purpose A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naïve patients with non–small-cell lung cancer. Patients and Methods Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. Results One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P = .19; grade 4 events: 39% v 48%, respectively; P = .30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. Conclusion Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated.
[O2‐03‐01]: Environmental enrichment mitigates cognitive deficits in APP/PS1 transgenic mice
Melnikova, Tatiana , Fadale, Daniel J., Xu, Guilian , Slunt, Hilda H., Gonzales, Victoria, Younkin, Linda H., Younkin, Steven G., Borchelt, David , Savonenko, Alena , Jankowsky, Joanna L.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.342 Get It

[P‐011]: Plasma AB levels as a premorbid biomarker for cognitive decline, mild cognitive impairment (MCI) and Alzheimer disease (AD)
Graff‐Radford, Neill R. , Lucas, John A. , Ivnik, Robert J., Younkin, Linda H., Petersen, Ronald C. , Younkin, Steven G. , Crook, Julia E. , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_1 | Pages: No page available

10.1016/j.jalz.2005.06.073 Get It

[AM‐02]: Natural history of amyloid‐beta peptides in the CNS and periphery
Younkin, Steven G.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_1 | Pages: No page available

10.1016/j.jalz.2005.06.029 Get It

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. Vincent , Hayman, Suzanne R. , Lacy, Martha Q. , Dispenzieri, Angela , Geyer, Susan M. , Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji , Greipp, Philip R., Fonseca, Rafaël , Lust, John A., Kyle, Robert A. , Russell, Stephen J. , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | August 23, 2005 | Volume: 106 | Issue: 13 | Pages: 4050-4053

10.1182/blood-2005-07-2817 | PMID 16118317 Get It

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given orally 25 mg daily on days 1 to 21 of a 28-day cycle. Dexamethasone was given orally 40 mg daily on days 1 to 4, 9 to 12, and 17 to 20 of each cycle. Objective response was defined as a decrease in serum monoclonal protein level by 50% or greater and a decrease in urine M protein level by at least 90% or to a level less than 200 mg/24 hours, confirmed by 2 consecutive determinations at least 4 weeks apart. Thirty-one of 34 patients achieved an objective response, including 2 (6%) achieving complete response (CR) and 11 (32%) meeting criteria for both very good partial response and near complete response, resulting in an overall objective response rate of 91%. Of the 3 remaining patients not achieving an objective response, 2 had minor response (MR) and one had stable disease. Fortyseven percent of patients experienced grade III or higher nonhematologic toxicity, most commonly fatigue (15%), muscle weakness (6%), anxiety (6%), pneumonitis (6%), and rash (6%). Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma.